David Willms, MD
Pulmonary Disease · San Diego, CANPI 1285626747
Payments from drug & device makers
Across 64 payments — averaging $742.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- La Jolla Pharmaceutical Company$40K
- Portola Pharmaceuticals, LLC$3K
- BTG International Inc.$2K
- BD$1K
- Inari Medical, Inc.$172
- Abiomed$126
- plus $467 from 6 others
What the payments were for
- Consulting fees$3,1757%
- Speaking & faculty fees$40,84986%
- Travel & lodging$1,1362%
- Food & beverage$2,3315%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| La Jolla Pharmaceutical Company | 44 | $40,121 |
| Portola Pharmaceuticals, LLC | 9 | $3,005 |
| BTG International Inc. | 1 | $2,450 |
| BD | 2 | $1,150 |
| Inari Medical, Inc. | 1 | $172 |
| Abiomed | 1 | $126 |
| Alcresta Therapeutics, Inc. | 1 | $124 |
| Exthera Medical Corporation | 1 | $118 |
| Intuitive Surgical | 1 | $112 |
| Medtronic | 1 | $69 |
| Getinge USA Sales, LLC | 1 | $28 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GIAPREZA$39,171
- ANDEXXA$2,876
- BD BBL Gram Iodine (Stabilized)$550
- FLOWTRIEVER CATHETER, S$172
- CT THROMBECTOMY SYSTEM KIT$172
- Impella$126
- RELIZORB$124
- Da Vinci Surgical System$112
How this compares
$47,492 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium-AlbuterolIpratropium/Albuterol Sulfate | 31 | $597 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in San Diego
- Edward FedermanSan Diego$3.6M
- David PochSan Diego$1.5M
- Shari BrazinskySan Diego$522K
- Samir MakaniSan Diego$371K
- George ChengSan Diego$309K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.